<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01201720</url>
  </required_header>
  <id_info>
    <org_study_id>IG0905</org_study_id>
    <secondary_id>2010-021360-15</secondary_id>
    <nct_id>NCT01201720</nct_id>
  </id_info>
  <brief_title>Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With &quot;Acute-on-chronic Liver Failure&quot;</brief_title>
  <official_title>Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Liver Failure&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joan Albert Arnaiz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Grifols, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on
      albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic
      patients with &quot;acute-on-chronic liver failure&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on
      albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic
      patients with &quot;acute-on-chronic liver failure&quot;, renal disfunction, cerebral disfunction ,and
      inflamtory response
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Albumin functional capacity</measure>
    <time_frame>10 days</time_frame>
    <description>Albumin binding capacity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin functional capacity</measure>
    <time_frame>10 days</time_frame>
    <description>Electron Paramagnetic Resonance Spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin functional capacity</measure>
    <time_frame>10 days</time_frame>
    <description>Ischemia-modified albumin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulatory disfunction</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma renin activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulatory disfunction</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentration of noradrenaline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulatory disfunction</measure>
    <time_frame>11 days</time_frame>
    <description>Systemic hemodynamic study and portal venous pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of blood urea nitrogen</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic encephalopathy graded with the West Haven Criteria</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic function parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Conventional hepatic function parameters: aspartate transaminase, alanine transaminase, gamma-glutamyl transferase, alkaline phosphatase, total, conjugated and not conjugated serum bilirubin, serum albumin, international normalized ratio (INR) and prothrombin index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of serum creatinine</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of sodium</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of potassium</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of phosphorus</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic toxins</measure>
    <time_frame>10 days</time_frame>
    <description>Hepatic toxin concentration: biliary acids, aromatic amino acids, ammonium and lactatum.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Plasma exchange with albumin</intervention_name>
    <description>Realization of 6 plasma exchange with albumin in 11 days</description>
    <arm_group_label>Albumin</arm_group_label>
    <other_name>Albumina grifols 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 80 years old

          -  Hepatic cirrhosis diagnosed by biopsy or clinical, analytic and ultra sound data.

          -  acute on chronic liver failure: defined by an acute deterioration in hepatic function
             produced in 2-4 weeks with jaundice (total serum bilirubin ≥ 5 mg/dl ) and hepatic
             encephalopathy (≥ grade 2) and/or renal insufficiency (serum creatinine ≥ 2 mg/dl)

        Exclusion Criteria:

          -  Neoplasm disease including hepatocarcinoma which exceed Milan criteria (1 tumour &gt;
             5cm, up to 3 tumours &lt;3 cm)

          -  Active bacterial or fungal infection with hemodynamic instability which require the
             utilization of vasoactive drugs at moderate dose (&gt;0,5 μg/Kg/min of noradrenaline)

          -  Structural moderate to severe cardiopathy (Cardiac Index &lt;2l/min/m2)

          -  Chronic renal insufficiency in treatment with haemodialysis

          -  Chronic moderate o severe pulmonary disease (maximum expiratory volume in a second
             &lt;50%)

          -  Active transplant

          -  human immunodeficiency virus infection

          -  Pregnancy or lactation

          -  Acute respiratory distress syndrome (P02/Fi02&lt; 200mm Hg) or acute lung injury
             (P02/Fi02&lt; 300mm Hg)

          -  Hemodynamic instability (&gt;0,5 μg/Kg/min of noradrenaline)

          -  Bleeding in the digestive tract in the previous 72h to the treatment

          -  Severe coagulopathy: INR ≥ 3.0 (Quick ≤ 20%) and/or platelets &lt; 30000//mm3

          -  Extrahepatic cholestasis

          -  Hepatobiliary surgery in the last 6 months (except laparoscopic Cholecystectomy)

          -  Concentrations bilirubin ≥ 5mg/dl during the period above 4 weeks previous to
             inclusion

          -  Concomitant participation in an other clinical trial

          -  Drug addiction

          -  Mental status which does not allow the patient to understand the trial, with the
             exception of hepatic encephalopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Arroyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Grifols, S.A.</investigator_affiliation>
    <investigator_full_name>Joan Albert Arnaiz</investigator_full_name>
    <investigator_title>CLINICAL TRIAL COORDINATOR</investigator_title>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>cirrhotic patients with acute on chronic liver failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

